Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T01:19:53.635Z Has data issue: false hasContentIssue false
  • English
  • Français

Trenimon Treatment in Chronic Hemoblastoses

Published online by Cambridge University Press:  01 August 2014

N. Quattrin ,
E. Dini  and
R. Montuori
N. Quattrin
Affiliation:
Reparto di Ematologia degli Ospedali Riuniti di Napoli
E. Dini
Affiliation:
Reparto di Ematologia degli Ospedali Riuniti di Napoli
R. Montuori
Affiliation:
Reparto di Ematologia degli Ospedali Riuniti di Napoli

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

1. Trenimon has three remarkable pharmacological characteristics, namely: very low toxicity, easy way of employing, big therapeutic action.

2. It results particularly useful in lymphatic and myeloid chronic leukemias, Vaquez's disease, hemorrhagic thrombocythemia, Waldenstrom's disease. It has to be noticed that Trenimon action is valuable in chronic myeloid leukemia even when it has been already treated with Busulphan for a long time.

3. Good results are obtained also in several cases of Hodgkin's disease, while the drug is less efficacious in Lympho-reticulosarcoma. Uncertain still being its action in plasmacytoma.

Type
Research Article
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 17 , Issue 1 , January 1968 , pp. 145 - 152
Copyright
Copyright © The International Society for Twin Studies 1968

References

Dini, E., Quattrin, N. (1965). Traitement des hémoblastoses chroniques par de nouveaux médicaments anti-blastiques (C 69 et Trénimon). X Congr. Eur. Hémat., Strasbourg, 1965 (sous presse).Google Scholar
Linke, A. (1960). Die Behandlung der Haemoblastosen und malignen Tumoren mit Tris-äthyleniminebenze-chinon. Deutsch. Med. Wschr., 75: 1928.CrossRefGoogle Scholar
Linke, A. (1964). Grenzen und Möglichkeiten einer Chemotherapie der Haemoblastosen und malignen Tumoren. Regensb. Jahrb. Arztl. Fortbild., XII, 3: 196.Google Scholar
Quattrin, N. et al. (1962). Primi risultati terapeutici sull'impiego del Trenimon nelle emoblastosi croniche. Clin. Terap., 7: 585.Google Scholar
Linke, A. et al. (1965). Tre anni di esperienza clinica con Trenimon nel campo delle emoblastosi croniche. Policlinico (Pral.), 72: 693.Google Scholar
Linke, A. (1966). Trattamento delle emoblastosi croniche con nuovi citostatici. Minerva Med., 57: 1141.Google Scholar
Symposium sur la radiothérapie de la maladie de Hodgkin. (1966). Nouv. Rev. Franç. Hémat., 6: 1.Google Scholar